The effect of hypotensive drugs on intraocular lenses clarity.
Journal
Eye (London, England)
ISSN: 1476-5454
Titre abrégé: Eye (Lond)
Pays: England
ID NLM: 8703986
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
16
10
2021
accepted:
22
08
2022
revised:
19
05
2022
pmc-release:
01
06
2024
medline:
29
5
2023
pubmed:
8
9
2022
entrez:
7
9
2022
Statut:
ppublish
Résumé
To assess the effect of hypotensive drugs on light absorbance, discoloration, opacification and precipitate formation of IOLs. In this laboratory study, four types of IOLs (two hydrophilic-acrylic-L1 and L2, and two hydrophobic-acrylic-B1 and B2) were soaked in solutions containing Timolol-maleate 0.5%, Dorzolamide 2%, Brimonidine-tartrate 0.2%, Latanoprost 0.005%, Brimonidine-tartrate/Timolol-maleate 0.2%/0.5% and Dorzolamide/Timolol-maleate 2%/0.5%. Non-treated IOLs and IOLs soaked in balanced salt solution (BSS) served as controls. All Treated lenses were sealed in containers and placed in an oven at 82 degrees Celsius for 120 days. Each IOL was examined using four different techniques: light microscopy imaging, light absorbance measurements at 550 nanometers through the optic's center, assessment of by a scanning electron microscope (SEM), and energy dispersive Xray spectrometry (EDX). Ninety-eight IOLs were included. All BSS-soaked IOLs appeared clear with no significant discoloration or precipitate-formation. Light absorbance in these lenses was comparable to that of non-soaked, non-heated IOLs. No calcium or phosphate were detected in either of these groups. Light absorbance differed significantly between the four treated IOL types. The drops most affecting light absorbance differed between IOLs. Gross examination revealed brown and yellow discoloration of all IOLs soaked in Dorzolamide and Brimonidine-tartrate solutions, respectively. SEM demonstrated precipitates that differed in size, morphology and distribution, between different IOL-solution combinations. EDX's demonstrated the presence calcium and phosphor in the majority of precipitates and the presence of sulfur in brown discolored IOLs. In vitro, interactions between hypotensive drugs and IOLs induce changes in light absorbance, discoloration and precipitate formation.
Identifiants
pubmed: 36071178
doi: 10.1038/s41433-022-02225-w
pii: 10.1038/s41433-022-02225-w
pmc: PMC10219955
doi:
Substances chimiques
dorzolamide
9JDX055TW1
Timolol
817W3C6175
Tartrates
0
Antihypertensive Agents
0
Brimonidine Tartrate
4S9CL2DY2H
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1696-1703Informations de copyright
© 2022. The Author(s), under exclusive licence to The Royal College of Ophthalmologists.
Références
World J Pharmacol. 2013;2(2):47-64
pubmed: 25590022
Arch Ophthalmol. 2005 Feb;123(2):186-92
pubmed: 15710814
Saudi J Ophthalmol. 2015 Oct-Dec;29(4):247-8
pubmed: 26586972
Eur J Ophthalmol. 2020 Sep;30(5):823-839
pubmed: 31387387
J Cataract Refract Surg. 2015 Jun;41(6):1310-4
pubmed: 26100959
J Cataract Refract Surg. 2009 Dec;35(12):2121-6
pubmed: 19969218
J Glaucoma. 2008 Aug;17(5):350-5
pubmed: 18703943
Ophthalmology. 2011 Feb;118(2):426.e1
pubmed: 21292116
Vestn Oftalmol. 2015 May-Jun;131(3):64-70
pubmed: 26310010
J Cataract Refract Surg. 2014 Jan;40(1):121-8
pubmed: 24269137
Ophthalmology. 2008 Jan;115(1):73-9
pubmed: 17498804
Ophthalmology. 2000 Dec;107(12):2179-85
pubmed: 11097592
J Cataract Refract Surg. 2016 Sep;42(9):1324-1331
pubmed: 27697251
J Cataract Refract Surg. 2007 Apr;33(4):713-26
pubmed: 17397749
J Glaucoma. 2017 Apr;26(4):349-355
pubmed: 28221327
J Cataract Refract Surg. 2012 Jul;38(7):1119-20
pubmed: 22727278
Am J Ophthalmol. 2016 Aug;168:68-77
pubmed: 27130371
Eye (Lond). 2003 Apr;17(3):393-406
pubmed: 12724703
J Cataract Refract Surg. 2020 Dec;46(12):1596-1603
pubmed: 33259388
J Cataract Refract Surg. 2018 Feb;44(2):219-225
pubmed: 29587977
Am J Ophthalmol. 2018 Sep;193:10-19
pubmed: 29890164
Tokai J Exp Clin Med. 2012 Sep 20;37(3):62-5
pubmed: 23032245
Indian J Ophthalmol. 2011 Jan;59 Suppl:S88-92
pubmed: 21150040
J Cataract Refract Surg. 2018 May;44(5):615-622
pubmed: 29891155
J Cataract Refract Surg. 2012 Aug;38(8):1476-85
pubmed: 22814055
Am J Ophthalmol. 2013 Jan;155(1):73-82.e1
pubmed: 23036570
Acta Ophthalmol. 2014 Sep;92(6):529-34
pubmed: 24119141
J Cataract Refract Surg. 2008 Mar;34(3):459-64
pubmed: 18299072
J Cataract Refract Surg. 2020 Jan;46(1):20-26
pubmed: 32050228
Indian J Ophthalmol. 2018 Jun;66(6):858-860
pubmed: 29786004
Graefes Arch Clin Exp Ophthalmol. 2014 Jan;252(1):125-30
pubmed: 24146269
Clin Ophthalmol. 2020 Oct 14;14:3343-3349
pubmed: 33116385
BMC Ophthalmol. 2015 Nov 25;15:170
pubmed: 26606985
Am J Ophthalmol. 2008 Jan;145(1):120-123
pubmed: 17915187
Ophthalmology. 2014 Nov;121(11):2081-90
pubmed: 24974815
PLoS One. 2016 Dec 1;11(12):e0166915
pubmed: 27907028
J Cataract Refract Surg. 1996 May;22(4):452-7
pubmed: 8733849
J Cataract Refract Surg. 2021 Sep 1;47(9):1210-1217
pubmed: 33315739
Curr Eye Res. 2015;40(10):969-81
pubmed: 25621973
Ophthalmology. 2021 Nov;128(11):e186-e194
pubmed: 32652203
Community Eye Health. 2000;13(34):17-9
pubmed: 17491949
PLoS One. 2016 Oct 27;11(10):e0165314
pubmed: 27788204
Biomed Opt Express. 2011 Feb 04;2(3):505-10
pubmed: 21412456
Open Ophthalmol J. 2010 Sep 03;4:52-9
pubmed: 21293732